ClinicalTrials.gg
CompletedNCT01150097Updated Nov 7, 2018Results posted

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

A Phase 3 interventional study of Tacrolimus (reduced tacrolimus) and Everolimus (reduced tacrolimus) in Liver Transplant Recipient, sponsored by Novartis Pharmaceuticals. Completed at 57 sites in 16 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients. The most important long-term safety assessments include evaluation of renal function, progression of HCV related allograft fibrosis, and other treatment related effects at Month 36 post-transplantation compared to extension baseline (Months 24 post-transplantation).

02

Conditions studied

  • Liver Transplant Recipient

Keywords

  • Liver transplantation
  • Everolimus
  • Calcineurin inhibitors
  • Tacrolimus
  • Renal function
  • Progression of HCV related allograft fibrosis
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Ability and willingness to adhere to study regimen
  • Completed core study with assigned regimen;

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  • Severe hypercholesterolemia or hypertriglyceridemia.
  • Low count.
  • Low white blood cell count.
  • Positive test for (HIV).
  • Systemic infection requiring active use of IV antibiotics.
  • Patients in a critical care setting.
  • Use of prohibited medication.
  • Use of agents not utilized in the protocol.
  • to any of the study drugs or similar drugs.
  • Pregnant or nursing (lactating) women
  • Women of not using a highly effective method of .

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Everolimus + reduced tacrolimus

    Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.

    Drug: Tacrolimus (reduced tacrolimus) · Drug: Everolimus (reduced tacrolimus) · Drug: Corticosteroids

  • Experimental
    Tacrolimus elimination

    Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.

    Drug: Tacrolimus (tacrolimus elimination) · Drug: Everolimus (tacrolimus elimination) · Drug: Corticosteroids

  • Active comparator
    Tacrolimus control

    Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.

    Drug: Tacrolimus (tacrolimus control) · Drug: Corticosteroids

Interventions

  • After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.

    Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic

  • Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.

    Also known as: RAD001,, Zortress,, Certican,, Afinitor

  • After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.

    Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic

  • Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.

    Also known as: RAD001,, Zortress,, Certican,, Afinitor

  • Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.

    Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic

  • DrugCorticosteroids

    For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death

    The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

    Time frame: from months 24 to 36

  2. Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death

    The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

    Time frame: from months 36 to 48

  3. Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death

    The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

    Time frame: from months 24 to 36

  4. Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death

    The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

    Time frame: from months 36 - 48

  5. Change in Renal Function

    Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m\^2) = 186.3\*(C\^-1.154)\*(A\^-0.203)\*G\*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.

    Time frame: from months 24 to 36

Secondary outcomes

  1. Incidence Rate of tBPAR

    The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.

    Time frame: from months 24 - 36

07

Results

Posted May 30, 2014

Participant flow

Two hundred eight four participants were eligible and enrolled into the extension. However, 2 participants withdrew from the extension prior to receiving treatment. Therefore, a total of 282 participants were accounted for in the extension.

Months 24 to 36 Post-transplantation
Participant flow — Months 24 to 36 Post-transplantation
MilestoneEverolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Started10651125
Completed9649117
Not completed1028
Withdrew: Death200
Withdrew: Administrative problems522
Withdrew: Lost to follow-up003
Withdrew: Withdrawal by subject303
Months 24 to 48 Post-transplantation
Participant flow — Months 24 to 48 Post-transplantation
MilestoneEverolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Started106510
Completed95470
Not completed1140
Withdrew: Administrative problems540
Withdrew: Withdrawal by subject400
Withdrew: Death200

Outcome measures

PrimaryIncidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death

The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

Time frame:
from months 24 to 36
Reported as:
Number · Participants
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death
ParticipantsEverolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death213
PrimaryIncidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death

The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

Time frame:
from months 36 to 48
Reported as:
Number · Participants
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death
ParticipantsEverolimus + Reduced TacrolimusTacrolimus Elimination
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death10
PrimaryIncidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death

The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

Time frame:
from months 24 to 36
Reported as:
Number · Participants
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death
ParticipantsEverolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death201
PrimaryIncidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death

The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.

Time frame:
from months 36 - 48
Reported as:
Number · Participants
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death
ParticipantsEverolimus + Reduced TacrolimusTacrolimus Elimination
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death00
SecondaryIncidence Rate of tBPAR

The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.

Time frame:
from months 24 - 36
Reported as:
Number · Participants
Incidence Rate of tBPAR
ParticipantsEverolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Incidence Rate of tBPAR012
PrimaryChange in Renal Function

Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m\^2) = 186.3\*(C\^-1.154)\*(A\^-0.203)\*G\*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.

Time frame:
from months 24 to 36
Reported as:
Mean · mL/min/1.73m^2
Change in Renal Function
mL/min/1.73m^2Everolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus Control
Change in Renal Function-0.9 ± 16.132.5 ± 12.40-3.3 ± 11.84

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reduced TAC, Month 36—32/106 (30.2%)38/106 (35.8%)
TAC Elimination, Month 36—16/51 (31.4%)29/51 (56.9%)
TAC Control, Month 36—28/125 (22.4%)43/125 (34.4%)
Reduced RAD + TAC, Month 48—34/106 (32.1%)43/106 (40.6%)
TAC Elimination, Month 48—24/51 (47.1%)36/51 (70.6%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventReduced TAC, Month 36TAC Elimination, Month 36TAC Control, Month 36Reduced RAD + TAC, Month 48TAC Elimination, Month 48
PyrexiaGeneral disorders3/1062/512/1253/1064/51
Incisional herniaInjury, poisoning and procedural complications1/1062/511/1252/1064/51
PneumoniaInfections and infestations2/1062/513/1253/1063/51
Impaired healingGeneral disorders2/1061/510/1252/1062/51
DiarrhoeaGastrointestinal disorders3/1060/512/1254/1060/51
Coronary artery stenosisCardiac disorders0/1060/510/1250/1061/51
Abdominal painGastrointestinal disorders1/1060/511/1251/1061/51
Abdominal strangulated herniaGastrointestinal disorders0/1061/510/1250/1061/51
Gastrointestinal obstructionGastrointestinal disorders0/1060/510/1250/1061/51
Intestinal obstructionGastrointestinal disorders0/1060/510/1250/1061/51
Most frequent other events
Showing 10 of 17
Most frequent other events
EventReduced TAC, Month 36TAC Elimination, Month 36TAC Control, Month 36Reduced RAD + TAC, Month 48TAC Elimination, Month 48
Incisional herniaInjury, poisoning and procedural complications2/1066/512/1252/1067/51
DiarrhoeaGastrointestinal disorders10/1063/514/12513/1064/51
FatigueGeneral disorders1/1062/5110/1252/1066/51
Oedema peripheralGeneral disorders4/1064/512/1256/1065/51
NasopharyngitisInfections and infestations5/1065/514/1256/1065/51
HypercholesterolaemiaMetabolism and nutrition disorders6/1064/513/1257/1065/51
Pain in extremityMusculoskeletal and connective tissue disorders2/1063/510/1252/1065/51
HypertensionVascular disorders8/1062/515/1259/1062/51
Renal failureRenal and urinary disorders1/1061/5110/1252/1061/51
ThrombocytopeniaBlood and lymphatic system disorders0/1061/511/1250/1064/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Everolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus ControlTotal
Mean53.5 ± 9.5754.9 ± 10.0755.2 ± 8.1054.5 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus + Reduced TacrolimusTacrolimus EliminationTacrolimus ControlTotal
Female29183885
Male773387197
08

Study locations

57 sites
  • Novartis Investigative Site
    Washington, District of Columbia 20007-2197, United States
  • Novartis Investigative Site
    Tampa, Florida 33606, United States
  • Novartis Investigative Site
    Lexington, Kentucky 40536, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202, United States
  • Novartis Investigative Site
    Rochester, Minnesota 55905, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Newark, New Jersey 07101, United States
  • Novartis Investigative Site
    New York, New York 10016, United States
  • Novartis Investigative Site
    New York, New York 10032, United States
  • Novartis Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29425, United States
  • Novartis Investigative Site
    Houston, Texas 77030-2400, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1118AAT, Argentina
  • Novartis Investigative Site
    San Martin, Buenos Aires C1107BEA, Argentina
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Bedford Park, South Australia 5041, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Rio de Janeiro, RJ 21041-030, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90020-090, Brazil
  • Novartis Investigative Site
    Cali, Valle Del Cauca, Colombia
  • Novartis Investigative Site
    Bogota, Colombia
  • Novartis Investigative Site
    Praha 4, Czech Republic 140 21, Czechia
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Clichy, 92110, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Villejuif, 94805, France
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Dublin 4, Ireland
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Rotterdam, 3015 CE, Netherlands
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Moscow, 129010, Russian Federation
  • Novartis Investigative Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    Baracaldo, Vizcaya 48903, Spain
  • Novartis Investigative Site
    Stockholm, 141 86, Sweden
  • Novartis Investigative Site
    Edinburgh, EH16 4SA, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2010 to primary completion in May 2013, 37 months.

Results were first posted in May 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2010
First posted
Jun 24, 2010
StartActual
Mar 31, 2010
Primary completionActual
May 3, 2013
CompletionActual
May 3, 2013
Results first posted
May 30, 2014
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01150097
Responsible party
Sponsor
First posted
Jun 24, 2010
Start date
Mar 31, 2010
Primary completion
May 3, 2013
Completion
May 3, 2013
Results posted
May 30, 2014
Last update
Nov 7, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion